External Source

Data Quality Expectations For Biosimilars With Case Studies (29of33) Quality – Oct. 16-17, 2019

2020 16:06
Synopsis
Merry Christie from the CDER Office of Biotechnology Products shares the need for a strong comparative analytical assessment.

You Might Also Like

Biosimilars and Interchangeables - Regulatory Highlights (27of33) Quality – Oct. 16-17, 2019 14:31
Biosimilars And Interchangeables - Regulatory Highlights (27...
2020
FDA Perspectives on Biosimilar BLA-Manufacturing (28of33) Quality – Oct. 16-17, 2019 24:48
Fda Perspectives On Biosimilar Bla-manufacturing (28of33) Qu...
2020
Data Requirements for Biosimilars 5:20
Data Requirements For Biosimilars
2018
Biosimilars Interchangeability 2:03
Biosimilars Interchangeability
2021
Biosimilars: Critical Quality Attributes 3:12
Biosimilars: Critical Quality Attributes
2021
Quality Considerations for Transition Biological Products (32of33) Quality – Oct. 16-17, 2019 15:58
Quality Considerations For Transition Biological Products (3...
2020
Biosimilars explained - HPRA 3:40
Biosimilars Explained - Hpra
2018
What's Health Canada Saying about Biosimilars? 2:52
What's Health Canada Saying About Biosimilars?
2021
Biologics and Biosimilars: Increasing Treatment Options 1:30
Biologics And Biosimilars: Increasing Treatment Options
2020
Fast Facts About the Regulatory Approval Pathway for Biosimilars – Amgen Science 1:44
Fast Facts About The Regulatory Approval Pathway For Biosimi...
2022
Fast Facts About the Quality of Biosimilars – Amgen Science 1:28
Fast Facts About The Quality Of Biosimilars – Amgen Scienc...
2022
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.